# The Journal of Health Design Recognising patient expertise in the search for a rare diagnosis



# Timothy J McLerran

Medical Intelligence One, San Diego, CA, USA

To Cite: McLerran T. Recognising patient expertise in the search for a rare diagnosis. JHD.2023;8(1):572–575. https://doi.org/10.21853/JHD.2023.200 Corresponding Author: Timothy J McLerran San Diego, CA, USA tmclerran@gmail.com	SUMMARY Enola is a tool to help with the diagnosis of rare diseases. It was initially designed for use by clinicians, but testing with the rare disease community provided two key design insights which changed the deployment strategy: 1) people in the rare disease community often learn the medical terminology relevant to their conditions and 2) out of necessity, many people with rare disease become the local, if not international, expert on their disorder. This led to the decision to deploy the tool as a web-based application which can be accessed by anyone. Key Words Rare disease; diagnostic odyssey; patient empowerment diagnostic assistance; human cognitive limits.
<b>Copyright:</b> ©2023 The Authors. Published by Archetype Health Pty Ltd. This is an open access article under the CC BY- NC-ND 4.0 license.	
	diagnostic assistance; human cognitive limits.

## INTRODUCTION

Physicians learn approximately 200 diseases in their medical training, yet greater than 10,000 rare diseases are known to exist.<sup>1</sup> This massive knowledge gap leaves patients who have rare disease searching for an average of 4–5 years before they reach a correct diagnosis.<sup>2</sup> Although any given rare disease is by definition rare, collectively rare diseases are conservatively estimated to affect 1 in 20 people.<sup>3</sup>

## SUMMARY

Diagnoses are missed when clinicians do not recognise the significance of a collection of signs and symptoms. This is especially problematic for rare diagnoses, where clinicians may have little to no knowledge of or experience with the patient's particular disease or syndrome.

To address this problem, an application named Enola was developed, which accepts clinical findings as input and returns a list of all rare diseases that have any association to the input findings, sorted by the probability of disease. Users review the suggested diagnoses and modify the search by confirming or denying their associated signs and symptoms. See an example search with an explanation of the interface (Figure 1).

Enola draws on well-established data sources that include  $\mathsf{Orphanet}^4$  and the Human Phenotype  $\mathsf{Ontology}.^5$ 

## LESSONS LEARNED

Enola was initially designed for use by clinicians, but testing with the rare disease community provided a critical design insight that completely changed the deployment strategy. When lay persons with rare diseases who already knew their diagnoses had access to Enola, they were often quite successful in finding their diagnosis again, simply by typing in their signs and symptoms.



#### Figure 1. Enola rare disease search tool

	Findings used in Search	Clear All
e.g. Thrombocytopenia, Occipital Encephalocele, Hypotonia		
Easy bruisability Petechiae		
Diseases		
Cutaneous collagenous vasculopath Cutaneous collagenous vasculopathy (CCV) is a primary micro Show All Findings  Rruising susceptibility Petechiae Vascular skin abnormality Skin rash	hy <pre>     </pre> I Diffuse telangiectasia     Promineur superficial blood vessels     Macule	0,000
<ul> <li>Osteopetrosis and related disorder</li> </ul>		

There is a search box at the top, with a toggle button that allows the user to specify whether the clinical finding they are adding to the list is present (positive sign) or absent (negative sign). All of the clinical findings included in the current search appear just below the search box. The search results appear on the remainder of the screen, under the heading "Diseases". Each disease appears in a blue-bordered box, with the disease name in bold at the top left, the incidence and/or prevalence value(s) at the top right, with a paragraph describing the disease underneath followed by associated clinical findings. Each clinical finding has a blue bar beside it indicating how frequently that finding is associated with the disease.

The key insights gained from these encounters were as follows:

- 1. People in the rare disease community often learn the medical terminology relevant to their conditions; and
- 2. Out of necessity, many people with rare diseases become the local, if not international, expert on their disorder. While their expertise may not come with the imprimatur of a medical school diploma, it often does empower them to make diagnoses that are later confirmed by clinicians, and to make well-informed decisions regarding their medical care.

Sometimes the physician's challenge is to educate the patient, and sometimes it is to recognise the patient's expertise, and to listen.

Thanks to these insights, Enola, the web-based rare disease search tool was deployed for beta testing.

#### **DESIGN INSIGHT**

This AI-powered application, which suggests possible rare diseases based upon a person's symptoms, integrates AI with a very *human-centered design approach* into the diagnosis process. What an interesting association between AI and *human-powered* design. Many people with rare

diseases, through their own dogged research, become the local or international experts on their disorder. In using a human-centered approach to finding and solving problems, designers seek out these types of *expert-users* to help uncover unmet needs that might never be noticed without their collaboration.

The authors continue to explore and deepen the robustness of their system by reviewing existing "solved" cases of rare diseases. Their user interface with its simple + and – to identify and filter symptoms makes this software appear easy to approach for clinicians and friendly to a user that might have a lesser knowledge of technical/medical language.

Although doctors are still considered the most reliable source of health information, studies reported on in 2006<sup>1</sup> and 2018<sup>2</sup> suggest people who face serious health needs turn to the internet—roughly 69 per cent of adults in the U.S. chose the internet and 15 per cent chose healthcare providers as their first source of health information, respectively. These findings suggest a strong need for reliable information for these *expertusers* and, indeed, the broader population beyond to help find solutions for rare diseases. Why not expand this AI-powered application to include the 200 diseases that are taught in medical schools to become a resilient system for clinical users as well as *expertusers*?

Joyce Thomas, MFA, IDSA Assistant Professor, Industrial Design Auburn University Auburn, Alabama

- 1. Bundorf MK, Wagner TH, Singer SJ, Baker LC. Who searches the internet for health information? *Health Serv Res.* 2006 Jun;41(3 Pt 1):819–36. doi: 10.1111/j.1475-6773.2006.00510.x
- Swoboda CM, Van Hulle JM, McAlearney AS, et al. Odds of talking to healthcare providers as the initial source of healthcare information: updated cross-sectional results from the Health Information National Trends Survey (HINTS). BMC Fam Pract. 2018;19:146. doi: 10.1186/s12875-018-0805-7

# REFERENCES

- Lamoreaux K, Lefebvre S, Levine D, et al. The Power of Being Counted. [online report] [Accessed 2023 January 26]. Available from: https://rare-x.org/case-studies/the-power-ofbeing-counted/
- Marwaha S, Knowles J, and Ashley E. A guide for the diagnosis of rare and undiagnosed disease: beyond the exome. *Genome Medicine*. 2022 February 28;14:23. doi: 10.1186/s13073-022-01026-w
- 3. Wakap, S, Lambert, D, Orly, A, et al. Estimating cumulative point prevalence of rare diseases: analysis of the Orphanet database. *European Journal of Human Genetics*. 2019 September 16;28:165–73. doi: 10.1038/s41431-019-0508-0
- Orphanet. The portal for rare diseases and orphan drugs. [Online]. [Accessed 2023 January 26]. Available from: <u>https://www.orpha.net/consor/cgi-bin/index.php</u>



The Monarch Initiative. The Human Phenotype Ontology. [Online]. [Accessed 2023 January 26]. Available from: https://hpo.jax.org/app/about

# ACKNOWLEDGEMENTS

The author would like to acknowledge the teams at Orphanet and The Monarch Initiative, who work hard to curate the primary sources of data that power Enola; Tim Allard, whose technical skill and design sensibility have made the Enola interface what it is; and the guidance and support of the rare disease community, whose hope carries us.

## **PEER REVIEW**

Not commissioned. Externally peer reviewed.

# **CONFLICTS OF INTEREST**

The authors owned Medical Intelligence One, a for-profit corporation that produced the Enola rare disease search tool. This company has since been dissolved.

FUNDING

None

ETHICS COMMITTEE APPROVAL

None